Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11554391 | 0.84 | NPC1 (0.49) | NPC1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL432494 | 0.80 | NPC1 (0.52) | NPC1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL28686366 | 0.77 | SMN1; SMN2 (0.56) | NPC1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL11086193 | 0.76 | KMT2A (0.45) | NPC1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL28146646 | 0.76 | RIPK1 (0.49) | NPC1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL10698414 | 0.75 | CYP2C19 (0.51) | NPC1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL16989810 | 0.73 | RIPK1 (0.46) | NPC1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL8823257 | 0.73 | ALDH1A1 (0.44) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL11192974 | 0.73 | NPC1 (0.85) | NPC1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL16989819 | 0.71 | RIPK1 (0.48) | NPC1RAB9AKMT2AMEN1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2562155-B1 | HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2019-06-05 | — | — | EP | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| EP-2562155-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | LCT, AGXT, HDAC9 | NPC1 3272/4885RAB9A 2523/4885KMT2A 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.